The abstract is read at the publisher; the summary is JClub's.
Cilengitide limits pro-fibrotic events in patient-derived vascular smooth muscle cells by targeting αV integrin, and is defined as the most effective promising drug for human TAAs.
- Why it matters: Thoracic aortic aneurysm lacks etiologic therapy, and unclear molecular mechanisms hinder targeted treatment. αV integrins are linked to TGF-β and mechanotransduction pathways, but their therapeutic role in syndromic and sporadic TAAs needs testing.
- What they did: The study measured higher αV integrin expression in both syndromic and sporadic human TAAs, then tested the αV integrin inhibitor Cilengitide in patient-derived VSMCs for pro-fibrotic effects. It also evaluated Cilengitide in vivo to compare therapeutic promise for human TAA treatment.
- The result: Cilengitide reduced pro-fibrotic events in patient-derived VSMCs and, in vivo, was identified as the most effective and promising drug for treating TAAs in humans. This supports αV integrin as a therapeutic target in both TAA types.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.